Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21; 385(9973):1107-13.